CORT Financial Facts

Basic and diluted net loss per share: -0.11
Research and development: 6.57M
See Full Income Statement

Commitments: 0
Additional paid-in capital: 313.53M
See Full Balance Sheet

Corcept Therapeutics (CORT) Earnings

  |   Expand Research on CORT
Next EPS Date 5/5/14 *Est. EPS Growth Rate -22.2% *Last Qtr.
Average EPS % Beat Rate +5.3% Revenue Growth Rate +197.1% *Last Qtr.
Average % Move 1-Wk after EPS -2.4% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
11/7/13 Q313 -$0.08-$0.12 +$0.04$2.6M$2.7M N/A +151.3% Details
8/8/13 Q213 -$0.10-$0.11 +$0.01$1.9M$2.72M N/A +112.7% Details
8/7/12 Q212 -$0.09-$0.11 +$0.02N/AN/A N/A +18.9% Details
5/3/12 Q112 -$0.13-$0.11 -$0.02N/AN/A N/A +11.7% Details
11/10/10 Q310 -$0.10-$0.10 $0.00N/AN/A N/A +11.4% Details
3/5/14 Q413 -$0.11-$0.10 -$0.01$4.1M$4.01M N/A +3.1% Details
3/9/11 Q410 -$0.10-$0.10 $0.00N/A$120K N/A +1.8% Details
11/7/11 Q311 -$0.08-$0.10 +$0.02N/AN/A N/A +27.2% Details